Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Tango Therapeutics has raised $600.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Tango Therapeutics's investors include RA Capital Management, Balyasny Asset Management, Cormorant Asset Management, Janus Henderson Investors, Gilead Sciences.
Tango Therapeutics is headquartered in Cambridge, United States.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Tango Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tango Therapeutics — Funding & Investors." VCBacked, June 9, 2026, https://www.vcbacked.co/company/tango-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Tango Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tango-therapeutics
{{cite web |title=Tango Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tango-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated